1. Home
  2. RAND vs PLUR Comparison

RAND vs PLUR Comparison

Compare RAND & PLUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Rand Capital Corporation

RAND

Rand Capital Corporation

HOLD

Current Price

$10.98

Market Cap

34.6M

Sector

Finance

ML Signal

HOLD

Logo Pluri Inc.

PLUR

Pluri Inc.

N/A

Current Price

$3.39

Market Cap

33.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
RAND
PLUR
Founded
1969
2001
Country
United States
Israel
Employees
N/A
N/A
Industry
Finance: Consumer Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
34.6M
33.9M
IPO Year
1996
2001

Fundamental Metrics

Financial Performance
Metric
RAND
PLUR
Price
$10.98
$3.39
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$12.00
AVG Volume (30 Days)
2.0K
5.1K
Earning Date
05-06-2026
05-08-2026
Dividend Yield
10.83%
N/A
EPS Growth
N/A
10.78
EPS
N/A
N/A
Revenue
N/A
$1,336,000.00
Revenue This Year
N/A
$97.38
Revenue Next Year
N/A
$293.97
P/E Ratio
N/A
N/A
Revenue Growth
N/A
309.82
52 Week Low
$10.05
$2.82
52 Week High
$20.00
$5.96

Technical Indicators

Market Signals
Indicator
RAND
PLUR
Relative Strength Index (RSI) 48.22 54.85
Support Level $10.53 $3.20
Resistance Level $11.15 $3.90
Average True Range (ATR) 0.25 0.13
MACD 0.02 -0.00
Stochastic Oscillator 36.15 57.45

Price Performance

Historical Comparison
RAND
PLUR

About RAND Rand Capital Corporation

Rand Capital Corp is a closed-end, externally managed, non-diversified investment company. Its investment objective is to generate current income and, when possible, complement its current income with capital appreciation by focusing its debt and related equity investments in privately-held, lower middle market companies with committed and experienced managements in a broad variety of industries. It predominantly invests in higher-yielding debt instruments.

About PLUR Pluri Inc.

Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.

Share on Social Networks: